Singer P.A., Daar A.S., Harnessing genomics and biotechnology to improve global health equity. „Science” 2001; 294: 87–89.

Hansel T.T., Kropshofer H, Singer T., The safety and side effects of monoclonal antibodies. Nature Rev. Drug Discov.” 2006; 9: 325–338.

Jahnz-Różyk K., Dostępność leków biologicznych w Polsce i na świecie. „Przewodnik Lekarza” 2010; 6: 14–16.

Hausmann O.V., Seitz M., Villiger P.M., Pichler W.J., The complex clinical picture of side effects to biologicals. „Med. Clin. North Am.” 2010; 94: 791–804.

Pichler J.W., Campi P., Adverse Side Effects to Biological Agents, w: Pichler W.J. (red.): Drug Hypersensitivity. Karger, Basel 2007: 151–165.

Purcell R.T., Lockey R.F., Immunologic responses to therapeutic biologic agents. „J. Investig. Allergol. Clin. Immunol.” 2008; 18(5): 335–342.

Schafer T., Epidemiology of psoriasis. „Review and the German Perspective Dermatology” 2006; 212, 4: 327–337.

Neneman A., Adamski Z., Aspekty kliniczne i epidemiologiczne zaburzeń ogólnoustrojowych u chorych na łuszczycę. „Forum Medycyny Rodzinnej” 2009; 3, 6, 447–453.

Henseler T., Christophers E., Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. „J. Am. Acad. Dermatol.” 1985; 13, 450–456.

Christophers E., Mrowietz U., Łuszczyca, w: Burgdorf W.H.C., Plewig G., Wolff H.H., Landthaler M. (red.). Gliński W. (red. pol.), Braun-Falco, Dermatologia. tłum. E. Trznadel-Budźko. Wydawnictwo Czelej, Lublin 2010; 526–546.

Pastuszka M., Tyc-Zdrojewska E., Uczniak S., Bienias W., Kaszuba A., Współczesne poglądy na etiopatogenezę łuszczycy. „Post. Dermatol. Alergol.” 2011; supl. 3: 117–131.

Lotti T., Hercogova J., Prignano F., The concept of psoriatic disease: can cutaneous psoriasis any longer be separated by the systemic comorbidities? „Dermatol. Ther.” 2010; 23, 119–122.

Gulliver W., Long-term prognosis in patients with psoria- sis. „Br. J. Derm.” 2008; 159 (supl. 2), 2–9.

Eder L., Chandran V., Shen H., Cook R.J., Shanmugarajah S., Rosen C.F. et al., Incidence of arthritis in a prospective cohort of psoriasis patients. „Arthritis Care Res.” 2011; 63: 619–622.

Miniszewska J., Jakość życia i poziom zasobów osobistych u osób chorych na łuszczycę, w: Rzepa T., Szepietowski J., Żaba R. (red.), Psychologiczne i medyczne aspekty chorób skóry. Wydawnictwo Conetis, Wrocław 2011; 7: 52–64.

Mrowietz U., Kragballe K., Reich K., Spuls P., Griffiths C.E., Nast A. et al., Definition of treatment goals for moderate to severe psoriasis a European consensus. „Arch. Dermatol. Res.” 2011; 303: 1–10.

Nestle F.O., Kaplan D.H., Barker J., Psoriasis. „N. Engl.J. Med.” 2009; 361(5): 496–509.

Ellis C.N., Krueger G.G., Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. „N. Engl. J. Med.” 2001; 345(4): 248–55.

Griffiths C.E., Biologics for psoriasis: current evidence and future use. „Br. J. Dermatol.” 2012; 167 supl. 3: 1–2.

Gan E.Y., Chong W.S., Tey H.L., Therapeutic Strategies in Psoriasis Patients with Psoriatic Arthritis: Focus on New Agents. „BioDrugs” 2013.

Szepietowski J., Zygmunt A., Chodorowska G., Gliński W., Kaszuba A., Placek W., Rudnicka L., Reich A., Rekomendacje Polskiego Towarzystwa Dermatologicznego dotyczące stosowania leków biologicznych w łuszczycy zwyczajnej i stawowej (łuszczycowym zapaleniu stawów). „Przegl. Dermatol.” 2010; 97: 1–13.

Hsu S., Papp K.A., Lebwohl M.G., Bagel J., Blauvelt A., Duffin K.C., Crowley J., Eichenfield L.F., Feldman S.R., Fiorentino D.F., Gelfand J.M., Gottlieb A.B., Jacobsen C., Kalb RE, Kavanaugh A., Korman N.J., Krueger G.G., Michelon M.A., Morison W., Ritchlin C.T., Stein Gold L., Stone S.P., Strober B.E., Van Voorhees A.S., Weiss S.C., Wanat K., Bebo B.F. Jr, Consensus guidelines for the man- agement of plaque psoriasis. „Arch. Dermatol.” 2012; 148(1): 95–102.

Papp K., Gulliver W., Lynde C., Poulin Y., Ashkenas J., Canadian Psoriasis Guidelines Committee, Canadian guidelines for the management of plaque psoriasis: overview. „J. Cutan Med. Surg.” 2011; 15(4): 210–219.

Nast A., Boehncke W.H., Mrowietz U., Ockenfels H.M., Philipp S., Reich K., Rosenbach T., Sammain A., Schlaeger M., Sebastian M., Sterry W., Streit V., Augustin M., Erd- mann R., Klaus J., Koza J., Müller S., Orzechowski H.D., Rosumeck S., Schmid-Ott G., Weberschock T., Rzany B., Deutsche Dermatologische Gesellschaft; Berufsver- band Deutscher Dermatologen, German S3-guidelines on the treatment of psoriasis vulgaris (short version). „Arch. Dermatol. Res.” 2012; 304(2): 87–113.

Moore A.Y., Richardson B.S., Long-term use of adalimumab in treatment of moderate to severe plaque psoriasis: a review of the literature. „Clin. Cosmet. Investig. Dermatol.” 2010; 3: 49–58.

Alwawi E., Mehlis S., Gordon K., Treating psoriasis with adalimumab.„Ther Clin. Risk Manag.” 2008; 4: 345–451.

Saurat J.H., Stingl G., Dubertret L. et al., Efficacy and safety results from the randomized controlled comparative study of adalimumab vs methotrexate vs. placebo in patients with psoriasis (CHAMPION). „Br. J. Dermatol.” 2008; 158: 558–566.

Turner D., Picot J., Cooper K., Loveman E., Adalimumab for the treatment of psoriasis. „Health Technol. Assess.” 2009; 13 supl. 2: 49–54.

Menter A., Tyring S.K., Gordon K. et al., Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial. „J. Am. Acad. Dermatol.” 2008; 58: 106–115.

Gordon K.B., Langley R.G., Leonardi C. et al., Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. „J. Am. Acad. Dermatol.” 2006; 55: 598–606.

Nguyen Y.U., Koo J., Etanercept in the treatment of plaque psoriasis. „Clin. Cosmet. Investig Dermatol.” 2009; 2: 77–84.

Menter A., Gottlieb A., Feldman S.R., Van Voorhees A.S., Leonardi C.L., Gordon K.B., et al., Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. „J. Am. Acad. Dermatol.” 2008; 58: 826–850.

Papp K.A., Tyring S., Lahfa M., Prinz J., Griffiths C.E., Nakanishi A.M. et al., A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. „Br. J. Dermatol.” 2005; 152: 1304–1312.

Leonardi C.L., Powers J.L., Matheson R.T., Goffe B.S., Zitnik R., Wang A. et al., Etanercept as monotherapy in patients with psoriasis. „N. Engl. J. Med.” 2003; 349: 2014–2022.

Tyring S., Gottlieb A., Papp K., Gordon K., Leonardi C., Wang A. et al., Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. „Lancet” 2006; 367: 29–35.

Tyring S., Gordon K.B., Poulin Y., Langley R.G., Gottlieb A.B., Dunn M. et al., Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis. „Arch. Dermatol.” 2007; 143: 719–726.

Paller A.S., Siegfried E.C., Langley R.G., Gottlieb A.B., Pa- riser D., Landells I. et al., Etanercept treatment for children and adolescents with plaque psoriasis. „N. Engl. J. Med.” 2008; 358: 241–251.

Leman J., Burden A., Treatment of severe psoriasis with infliximab. „Ther. Clin. Risk Manag.” 2008; 4(6): 1165–1176.

Sivamani R.K., Correa G., Ono Y., Bowen M.P., Raychaudhuri S.P., Maverakis E., Biological therapy of psoriasis. „In- dian J. Dermatol.” 2010; 55(2): 161–170.

Reich K., Nestle F.O., Papp K., Ortonne J.P., Evans R., Guzzo C. et al., Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. „Lancet” 2005; 366: 1367–1374.

Menter A., Feldman S.R., Weinstein G.D., Papp K., Evans R., Guzzo C. et al., A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoria- sis. „J. Am. Acad. Dermatol.” 2007; 56: 31.e-15.

Gottlieb A.B., Evans R., Li S., Dooley L.T., Guzzo C.A., Baker D. et al., Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. „J. Am. Acad. Dermatol.” 2004; 51: 534–542.

Toussirot E., Michel F., Béreau M., Binda D., Ustekinumab in chronic immune-mediated diseases: review of long term safety and patient improvement. „Patient Prefer Adherence” 2013;7: 369–377.

Krueger G.G., Langley R.G., Leonardi C. et al., A human interleukin 12/23 monoclonal antibody for the treatment of psoriasis. „N. Engl. J. Med.” 2007; 356(6): 580–592.

Leonardi C.L., Kimball A.B., Papp K.A. et al., Efficacy and safety of ustekinumab, a human interleukin-12/23 mono-clonal antibody in patients with psoriasis: 76 week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 1). „Lancet” 2008; 371 (9625): 1665–1674.

Papp K.A., Langley R.G., Lebwohl M. et al., Efficacy and safety of ustekinumab, a human interleukin-12/23 mono- clonal antibody in patients with psoriasis: 52 week results from a randomised, doubleblind, placebo-controlled trial (PHOENIX 2). „Lancet” 2008; 371(9625): 1675–1684.

Griffiths C.E.M., Strober B., van de Kerkhof P. et al., Comparison of ustekinumab and etanercept for moderate to severe psoriasis. „N. Engl. J. Med.” 2010; 362(2): 118–128.

Avgerinou G., Bassukas I., Chaidemenos G., Katsampas A., Kosmadaki M., Kousoulakou H., Petridis A., Schenkel B., Sotiriadis D., Spiliopoulos T., Stavropoulos P.,Toumpi E., Xaplanteris L., Budget impact analysis of ustekinum-ab in the management of moderate to severe psoriasis in Greece. „BMC Dermatol.” 2012; 12: 10.

Feldman S.R., Fleischer A.B., Reboussin D.M., Rapp S.R., Bradham D.D., Exum M.L. et al., The economic impact of psoriasis increases with psoriasis severity. „J. Am. Acad. Dermatol.” 1997; 37: 564–569; doi: 10.1016/S0190-9622(97)70172-5.

Finlay A.Y., Coles E.C., The effect of severe psoriasis on the quality of life of 369 patients. „Br. J. Dermatol.” 1995; 132: 236–244.

Schoffski O., Augustin M., Prinz J., Rauner K., Schubert E., Sohn S. et al., Costs and quality of life in patients with mod- erate to severe plaque-type psoriasis in Germany: a multi-center study. „J. Dtsch Dermatol. Ges.” 2007; 5: 209–218.

Ferrándiz C., García A., Blasco A.J., Lázaro P., Cost-efficacy of adalimumab, etanercept, infliximab and ustekinumab for moderate-to-severe plaque psoriasis. „J. Eur. Acad. Dermatol. Venereol.” 2012; 26(6): 768–777.

Kimball A.B., Bensimon A.G., Guerin A. et al., Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of re- sults from a randomized, double-blind, placebo-controlled, phase III trial. „American Journal of Clinical Dermato- logy” 2011; 12(1): 51–62.

Kimball A.B., Yu A.P., Signorovitch J. et al., The effects of adalimumab treatment and psoriasis severity on self-reported work productivity and activity impairment for patients with moderate to severe psoriasis. „Journal of the American Academy of Dermatology” 2012; 66(2): 67–76.